TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pasithea Therapeutics Corp ( (KTTA) ) has issued an update.
On September 16, 2025, Pasithea Therapeutics announced the activation of two clinical trial sites in South Korea for its Phase 1/1b open-label study of PAS-004 in adult participants with neurofibromatosis type 1 (NF1). The sites, Asan Medical Centre and Severance Hospital Yonsei University Health System, are actively recruiting participants, with the first patient already dosed. The trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of PAS-004, with initial interim data expected in the first quarter of 2026. This expansion into South Korea is seen as pivotal for the trial’s success, given the country’s significant NF1 patient population and the involvement of leading medical institutions.
More about Pasithea Therapeutics Corp
Pasithea Therapeutics Corp is a clinical-stage biotechnology company focused on the development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor. The company targets the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases, with ongoing clinical trials in advanced cancer patients and adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas.
Average Trading Volume: 136,204
Technical Sentiment Signal: Sell
Current Market Cap: $5.72M
See more data about KTTA stock on TipRanks’ Stock Analysis page.